HCA
EW icon

Heck Capital Advisors’s Edwards Lifesciences EW Stock Holding History

Heck Capital Advisors’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,179
Closed -$309K – 426
2024
Q4 		$309K Buy
+4,179
New +$292K 0.01% 229

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Heck Capital Advisors's EW Position: Q1 2025 in Review

Heck Capital Advisors sold out of Edwards Lifesciences (EW) in Q1 2025, closing a stake of 4,179 shares — an estimated $309K sold.

Heck Capital Advisors first reported a position in EW in Q4 2024 and held it in 1 quarter. The position peaked at $309K in Q4 2024. 1,205 funds tracked by Wall St. Rank hold EW as of Q1 2025.

  • Heck Capital Advisors reported no remaining Edwards Lifesciences position as of Q1 2025 after selling out during the quarter.
  • Heck Capital Advisors sold 4,179 Edwards Lifesciences shares in Q1 2025, an estimated $309K.
  • Heck Capital Advisors first reported a position in Edwards Lifesciences in Q4 2024 and held it in 1 quarter.
  • Heck Capital Advisors's Edwards Lifesciences position peaked at $309K in Q4 2024.
  • 1,205 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2025.

Based on Heck Capital Advisors's 13F filing for Q1 2025, filed 13 May 2025.